Shyamasundaran Kottilil MD PhD, MACP, FRCP, FIDSA, FAASLD

Infectious Disease•Baltimore, MD

Director

Join to View Full Profile

725 W Lombard StBaltimore, MD 21201
Phone+1 410-328-9102
Fax+1 410-706-4619

Education & Training

National Institutes of Health Clinical CenterFellowship, Infectious Disease, 2000 - 2002
Rhode Island Hospital/Brown University HealthResidency, Internal Medicine, 1997 - 2000
Government Medical College ThrissurClass of 1991

Certifications & Licensure

DC State Medical License 2009 - 2026
MD State Medical License 2014 - 2026
VA State Medical License 2001 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV Start of enrollment: 1993 Mar 09
RECRUITING
Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection Start of enrollment: 2010 Jul 01
Terminated
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection Start of enrollment: 2011 Aug 23
COMPLETED
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV Start of enrollment: 2011 Sep 01
Terminated
Phase 4
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Start of enrollment: 2019 Dec 01
Withdrawn
Phase 4
Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003) Start of enrollment: 2020 Aug 31
Terminated
Phase 2
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) Start of enrollment: 2020 Apr 24
Completed
Phase 3
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects Start of enrollment: 2023 Sep 27
Completed
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies.
Homie A Razavi, Imam Waked, Huma Qureshi, Loreta A Kondili, Ann-Sofi Duberg
Journal of Hepatology. 2025-02-04
A Sequential Mixed-Methods Study of Factors Associated with Low High-Resolution Anoscopy Completion in Transgender Women with Abnormal Anal Cytology.
Omar Harfouch, Darren Whitfield, Tural Mammadli, Rahwa Eyasu, Connor Volpi
AIDS Patient Care and Stds. 2025-02-01
1 citations
Leveraging Old Hepatitis C Therapies.
S Sean Tu, Shyamasundaran Kottilil, T Joseph Mattingly 2nd
The New England Journal of Medicine. 2024-12-28

Press Mentions

Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients with Unfavorable Treatment CharacteristicsA Randomized Clinical TrialSeptember 19th, 2019
UM School of Medicine Awarded Nearly $30 Million to Improve Health Outcomes of IV Drug UsersDecember 13th, 2023
UM School of Medicine Awarded Nearly $30 Million to Prevent Infections Associated with IV Drug UseDecember 21st, 2023

Grant Support

Novel therapy for alcoholic liver disease-associated hepatorenal syndromeMITOPOWER LLC2021–2026
Therapeutic Strategies For The Management Of HCV/HIV CO-National Institute Of Allergy And Infectious Diseases2006
Role Of Innate Immunity In The Initiation And PathogenesNational Institute Of Allergy And Infectious Diseases2006

Professional Memberships

American College of Physicians - ACP
Master